8-K - GBCS - Equibles

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM8-K

CURRENTREPORT

Pursuantto Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 9, 2021

SELECTISHEALTH, INC.

(Exact Name of Registrant as Specified in its Charter)

Utah	0-15415	87-0340206
(State<br> or other jurisdiction<br><br> <br>of<br> incorporation)	Commission<br><br> <br>File<br> Number	(I.R.S.<br> Employer<br><br> <br>Identification<br> number)

8480 E. Orchard Road, Suite 4900, Greenwood Village, CO 80111

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (720) 680-0808

(Former<br> name or former address, if changed since last report)
[ ]	Written<br> communications pursuant to Rule 425 under the Securities Act
---	---
[ ]	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act
[ ]	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act
[ ]	Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act

Securitiesregistered pursuant to Section 12(b) of the Act:

Title of each Class	Trading Symbol	Name of each exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

ITEM 3.02	UNREGISTERED SALE OF EQUITY SECURITIES

The following sets forth the information required by Item 701 of Regulation S-K with respect to the unregistered sales of equity securities by Selectis Health, Inc. (the “Company”) effective July 9, 2021.

a.	On<br> July 9, 2021, the Company sold 1,500,000 shares of Common Stock at a purchase price of $0.50 per share for a total amount<br> of $750,000.
b.	The<br> Common Stock was sold to nine (9) investors, each of whom qualified as an “accredited investor” within the meaning of<br> Rule 501(a) of Regulation D under the Securities Act of 1933 as amended (the “Securities Act”).
c.	The<br> offering was conducted through a registered broker-dealer acting as a Placement Agent. The Placement Agent was paid a cash commission<br> of 5% of the gross proceeds of the offering proceeds, except for a 2.5% commission on the proceeds of investments by directors and<br> officers of the Company and a 10% warrant coverage for investments from non-officer/director investors, exercisable for three years<br> at an exercise price of $0.50 per share.
d.	The<br> issuance of the Securities was undertaken without registration under the Securities Act in reliance upon an exemption from the registration<br> requirements of the Securities Act set forth in Rule 506(b) of Regulation D and Section 4(2) thereunder. The investors each qualified<br> as an “accredited investor” within the meaning of Rule 501(a) of Regulation D. In addition, the Securities, which were<br> taken for investment purposes and not for resale, were subject to restrictions on transfer. We did not engage in any public advertising<br> or general solicitation in connection with this transaction, and we provided the investor with disclosure of all aspects of our business,<br> including providing the investor with our reports filed with the Securities and Exchange Commission and other financial, business<br> and corporate information. Based on our investigation, we believed that the accredited investors obtained all information regarding<br> the Company that each requested, received answers to all questions posed and otherwise understood the risks of accepting our Securities<br> for investment purposes.
e.	The<br> Warrants noted in Item 3.02(c) above are exercisable to purchase 66,500 shares of Common Stock of the Company for three years at<br> an exercise price of $0.50 per share.
f.	The<br> proceeds will be used for general working capital.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Selectis Health, Inc.
	(Registrant)
Dated:<br> July 14, 2021	/s/ Lance Baller
	Lance<br> Baller, CEO